Bristol Myers Squibb Q3 2025: $12.2B Revenue, Guidance Up

On 2025-10-30, Bristol Myers Squibb reported third-quarter 2025 revenue of $12.2 billion, a 3% increase. Management also announced that it is raising guidance for full-year 2025. Those are the only confirmed items provided in this report. A 3% revenue increase accompanied by an upward revision to year guidance generally signals stronger-than-expected operating performance or improved near-term outlook from management. For investors, the guidance raise is the key development: it represents management's view of the remainder of the year but requires the company's full release or management commentary to understand drivers and scope. Without additional line-item details in the information supplied here, prudent next steps for investors are to review the company's full earnings release and any accompanying management commentary or investor presentation to identify which products, regions or business units drove the quarter and the guidance change.